Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Relay Therapeutics, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 25, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076739
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Other liabilities | (1,527) | 786 | (24,948) |
| Net cash used in operating activities | (235,455) | (249,107) | (300,316) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (410) | (2,018) | (4,126) |
| Purchases of investments | (122,971) | (650,629) | (385,542) |
| Proceeds from maturities and sales of investments | 316,180 | 611,564 | 647,302 |
| Net cash provided by (used in) investing activities | 192,799 | (41,083) | 257,634 |
| Cash flows from financing activities: |
Item 16. Form 10-K Summary
FAQ
- What is Relay Therapeutics, Inc.'s capex?
- Relay Therapeutics, Inc. (RLAY) reported capex of $1K in Q4 2025.
- What is the long-term trend for Relay Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s capex has grown at a -41.3% compound annual growth rate (CAGR), from $3.47M to $411K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Relay Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude